Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VH4524184 + phenytoin
- Development stage
- Unknown
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VH4524184 + phenytoin is an investigational drug combination consisting of the novel small molecule anticonvulsant VH4524184 and the established anti-epileptic drug phenytoin. VH4524184 is a new chemical entity (NCE) currently being developed by Viatris, which entered Phase 1 clinical development in 2023 for the treatment of epilepsy. Phenytoin is a classic anticonvulsant that acts as a non-selective blocker of voltage-gated sodium channels. This specific combination is primarily utilized in clinical pharmacology studies (such as NCT05848427) to evaluate the potential for drug-drug interactions (DDI). Specifically, researchers are investigating the effect of VH4524184 on the pharmacokinetics of phenytoin, which is a known substrate for the cytochrome P450 enzymes CYP2C9 and CYP2C19. These studies are essential for establishing the safety profile and appropriate dosing regimens for VH4524184 when used in conjunction with standard-of-care seizure medications.
- Other names
- VH4524184 + phenytoin sodium
02
Targets
NaV (Voltage-gated sodium channels)Integrase allosteric pocket (HIV)
Beyond the preview
Go deeper on VH4524184 + phenytoin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VH4524184 + phenytoin.